Michael Wang, MD | Authors

Articles

Fitting Zanubrutinib into the Treatment Landscape for Mantle Cell Lymphoma

September 27, 2019

Michael Wang, MD, discusses the potential role for the next-generation Bruton's tyrosine kinase inhibitor zanubrutinib compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma.